Location
Headquarters: San Carlos, California, United States, North America
Region: California
Country: US
Continent: North America
About
Natera is a global leader in molecular diagnostics focused on cell-free DNA testing for oncology, women’s health, and organ health. The company develops cfDNA-based tests to inform personalized care decisions, including tumor profiling, hereditary cancer screening, and transplant assessments, with laboratories that are CAP/CLIA-certified and ISO 13485 certified. Its offerings span across oncology, prenatal and pregnancy genetics, and organ health, serving patients and clinicians worldwide. Natera emphasizes integrating test information into healthcare decisions and highlights extensive clinical validation and millions of patient studies in its portfolio.
Natera develops cell-free DNA testing solutions for oncology, women's health, and organ health. Its products include Signatera for cancer monitoring, Panorama for prenatal screening, and Prospera for transplant rejection assessment. The company serves healthcare providers and patients globally through its CLIA-certified laboratories.
Natera Inc.
2004
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
680900000
over-1b
ipo
NASDAQ:NTRA
nasdaq
Investors
Founders
Jonathan Sheena
Matthew Rabinowitz
Leadership
Technology Stack
Products
Signatera™ Genome: A tumor-informed molecular residual disease (MRD) assay that detects cancer recurrence and monitors treatment response using cell-free DNA.
Altera™: A tumor genomic profiling test that identifies DNA and RNA biomarkers to inform cancer treatment options and clinical trial eligibility.
Latitude™: A blood-based, tissue-free test for detecting molecular residual disease (MRD) in cancer patients without requiring tumor tissue.
Empower™: A hereditary cancer test that identifies germline mutations associated with increased cancer risk, available with a rapid STAT option.
Prospera Kidney: A transplant assessment test that detects kidney organ injury early to inform treatment strategies and improve transplant outcomes.
Prospera Heart: A transplant assessment test that detects heart organ injury early to guide treatment and improve transplant health.
Funding rounds
POST_IPO_EQUITY · 250000000 · (2023-09-01T00:00:00)
POST_IPO_CONVERTIBLE · 250000000 · (2020-04-01T00:00:00)
IPO · 180000000 · (2015-06-01T00:00:00)
SERIES_F · 55500000 · (2015-04-01T00:00:00)
SERIES_E · 54600000 · (2013-05-01T00:00:00) · Lead: Lightspeed Venture Partners
SERIES_D · 20000000 · (2012-01-01T00:00:00) · Lead: Lightspeed Venture Partners
GRANT · 2000000 · (2011-04-01T00:00:00)
SERIES_C · 12000000 · (2010-11-01T00:00:00)
SERIES_B · 6000000 · (2009-01-01T00:00:00)
SERIES_A · 4000000 · (2008-12-01T00:00:00)